To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
363
Phosphate buffered saline placebo for injection
Investigational Site
Oudenaarde, Minderbroederstaraat, Belgium
Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade Response
A CR-SMFRS response is defined as at least a 1-point improvement (i.e. 1-point reduction) from Baseline 12 weeks after the last treatment. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Percentage of Participants With a Subject Self Rating Scale (SSRS) Response
A SSRS response is defined as an SSRS score that is 4 or greater 12 weeks after the last treatment. The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Percentage of Participants With a CR-SMFRS 2-grade Response
A CR-SMFRS 2-grade response is defined as at least a 2-point improvement (i.e. 2-point reduction) from Baseline 12 weeks after the last treatment. The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Change From Baseline in CR-SMFRS Scores
The CR-SMFRS score is based on the investigator's clinical evaluation of the participant, where submental fullness is scored on a 5-point ordinal scale (0-4) with 0 = absent, 1 = mild, 2 = moderate, 3 = severe, and 4 = extreme. A negative change from Baseline indicates improvement.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Investigational Site
Arras, France
Investigational Site
Cannes, France
Investigational Site
Nice, France
Investigational Site
Pantin, France
Investigational Site
Paris, France
Investigational Site
Paris, France
Investigational Site
Augsburg, Germany
Investigational Site
Augsburg, Germany
Investigational Site
Berlin, Germany
...and 20 more locations
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Change From Baseline in SSRS Scores
The SSRS assesses participant's satisfaction with their appearance in association with the face and chin on a 7-point scale from 0 to 6: where 0 = Extremely dissatisfied, 1 = Dissatisfied, 2 = Slightly dissatisfied, 3 = Neither satisfied nor dissatisfied, 4 = Slightly satisfied, 5 = Satisfied and 6 = Extremely satisfied. A positive change from Baseline indicates improvement.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Change From Baseline in Submental Fat Thickness
Submental thickness was measured using caliper devices.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Change From Baseline in Patient-reported Submental Fat Rating Scale (PR-SMFRS)
The PR-SMFRS is based on the participant's response to the question "How much fat do you currently have under your chin?" answered on a 5-point ordinal scale (0-4) with 0 = no chin fat at all, 1 = a slight amount of chin fat, 2 = a moderate amount of chin fat, 3 = a large amount of chin fat, and 4 = a very large amount of chin fat. Improvement is defined as any decrease in score and worsened as any increase in score.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Change From Baseline in Patient-Reported Submental Fat Impact Scale (PR-SMFIS)
The PR-SMFIS assesses the impact of submental fat on self-perception of 6 characteristics related to the appearance of submental fullness as evaluated by the participant. Each item is rated on an 11-point numeric scale from 0 to 10.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Change From Baseline in Self-rating of Attractiveness
Self-rating of attractiveness assesses aspects of appearance from the participant's perspective by a series of 6 questions: How attractive do you think your overall appearance (chin/neck, eyes, nose, mouth, entire face) is/are?" Each question was answered on a scale from 1 to 9 where 1 = Not at all attractive, 5 = Neither attractive nor unattractive and 9 = Extremely attractive. A positive change from Baseline indicates improvement.
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Change From Baseline in Derriford Appearance Scale 24 (DAS24)
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
Change From Baseline in Body Image Quality of Life Inventory (BIQLI)
Time frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)